Skip to content
Inciteful Med

The Biology and Genetics of Beta-Thalassemia Major

Last updated:

Beta-thalassemia major is an inherited blood disorder caused by mutations in the HBB gene. Children with this condition cannot produce enough beta-globin, leading to severe anemia. Both parents must pass down a mutated gene for a child to inherit the major form of the disease.

Key Takeaways

  • • Beta-thalassemia major is caused by mutations in the HBB gene, preventing the body from making enough beta-globin for healthy red blood cells.
  • • The beta-zero mutation produces no beta-globin, while the beta-plus mutation produces a severely reduced amount.
  • • Unpaired alpha-globin chains clump together and destroy red blood cells in the bone marrow, causing a severe form of anemia.
  • • Symptoms typically do not appear until a baby is 3 to 6 months old, when protective fetal hemoglobin levels naturally decrease.
  • • The condition is autosomal recessive, meaning a child must inherit one mutated gene from each parent to develop Beta-thalassemia major.

Understanding the biology of Beta-thalassemia major (also known as Cooley’s Anemia) starts with the HBB gene [1]. This gene acts as a blueprint for making beta-globin, a vital part of hemoglobin [1][2]. Hemoglobin is the protein inside red blood cells that picks up oxygen in the lungs and delivers it to the rest of the body [3].

In a child with Beta-thalassemia major, mutations in the HBB gene mean the body cannot make enough beta-globin [2][4]. This creates a chain reaction that affects how red blood cells are built and how long they live [5][6].

The β0\beta^0 vs. β+\beta^+ Mutation

Doctors use the terms β0\beta^0 (beta-zero) and β+\beta^+ (beta-plus) to describe how much beta-globin a person’s body can make [4]:

  • β0\beta^0 (Beta-Zero): This mutation means the gene provides no instructions at all. The body produces zero beta-globin from that gene [7][8].
  • β+\beta^+ (Beta-Plus): This mutation means the gene works partially. The body produces some beta-globin, but much less than it should [4][8].

A child with Beta-thalassemia major usually inherits two “severe” mutations (one from each parent), such as β0/β0\beta^0/\beta^0 or a combination of β0/β+\beta^0/\beta^+ [4][9]. The β0/β0\beta^0/\beta^0 genotype is typically the most severe form because there is a total absence of functional beta-globin [2][10].

The Alpha and Beta Imbalance

To make healthy hemoglobin, the body needs an equal number of alpha-globin chains and beta-globin chains [3]. They are designed to “partner up” in pairs [11].

In your child’s case, because they lack beta-globin, the alpha-globin chains are left without partners [5][11]. These “lonely” alpha chains are actually toxic to red blood cells [12][13]. They clump together and damage the cell from the inside [5][6].

Ineffective Erythropoiesis

This leads to a process called ineffective erythropoiesis [12]. Think of the bone marrow as a factory for red blood cells. Because the cells are being built with “faulty parts” (unpaired alpha chains), the factory’s quality control system recognizes they are broken and destroys them before they can even leave the bone marrow and enter the bloodstream [12][14]. As a result, the body is constantly working hard to make blood, but very few healthy cells actually make it out into circulation [11][15].

Why Symptoms Don’t Appear Immediately

You may wonder why your child seemed perfectly healthy at birth. This is because of Fetal Hemoglobin (HbF) [16]. Before birth and for the first few months of life, babies have a special kind of hemoglobin that uses gamma-globin instead of beta-globin to pair with alpha-globin [17][18].

Around 3 to 6 months after birth, the body naturally flips a “genetic switch” to stop making fetal hemoglobin and start making adult hemoglobin [18][19]. For most children, this is a smooth transition [18]. But for a child with Beta-thalassemia major, as the “protective” fetal hemoglobin levels drop, the lack of beta-globin becomes apparent, and symptoms of severe anemia begin to emerge [16][20].

How the Condition is Inherited

Beta-thalassemia major is an autosomal recessive condition [21]. This means a child must inherit one mutated gene from each parent to have the “major” form of the disease [21].

  • Carrier (Beta-Thalassemia Trait): If a person has only one mutated gene, they are a carrier [21]. Most carriers have no symptoms or only very mild anemia [21][22]. They often don’t even know they have the trait unless they have a specialized blood test [21].
  • Inheritance Patterns: If both parents are carriers, for each pregnancy there is a:
    • 25% chance the child will have Beta-thalassemia major [21][23].
    • 50% chance the child will be a carrier (like the parents) [21].
    • 25% chance the child will not have the mutation at all [21].

Importantly, if only one parent is a carrier and the other is not, the child cannot inherit Beta-thalassemia major [21]. This is often a significant source of relief for extended families.

Frequently Asked Questions

What is the difference between beta-zero and beta-plus mutations?
A beta-zero mutation means the gene provides no instructions, so the body produces zero beta-globin from that gene. A beta-plus mutation means the gene works partially, producing a small but insufficient amount of beta-globin.
Why do symptoms of Beta-thalassemia major not appear immediately after birth?
Babies are born with fetal hemoglobin, which protects them because it does not require beta-globin to function properly. Around 3 to 6 months of age, the body switches to making adult hemoglobin, which reveals the beta-globin deficiency and causes anemia symptoms to appear.
Why does a lack of beta-globin damage red blood cells?
Without enough beta-globin to partner with, alpha-globin chains are left unpaired. These unpaired chains are toxic to red blood cells, causing them to clump together and destroy the cells inside the bone marrow before they can enter the bloodstream.
How is Beta-thalassemia major inherited?
The condition is autosomal recessive, meaning a child must inherit one mutated HBB gene from each parent. If both parents are carriers, there is a 25 percent chance with each pregnancy that their child will have Beta-thalassemia major.
If only one parent is a carrier, can our child get Beta-thalassemia major?
No. If only one parent is a carrier of the beta-thalassemia trait and the other is not, the child cannot inherit the severe major form of the disease. The child might inherit the trait and become a carrier, but they will not have Beta-thalassemia major.

Questions for Your Doctor

  • • Is my child's mutation classified as $\beta^0$ (beta-zero) or $\beta^+$ (beta-plus), and what does that mean for their transfusion schedule?
  • • Can you explain my child's specific alpha-globin to beta-globin 'imbalance' based on their genetic testing?
  • • When should we start regular monitoring of fetal hemoglobin (HbF) levels?
  • • How often should we monitor for bone marrow expansion, and what are the early signs?
  • • Are there specific genetic modifiers my child has that might make their symptoms more or less severe?

Questions for You

  • • Do I have a copy of our family's genetic testing results to share with other relatives who may be at risk of being carriers?
  • • Did I notice any specific changes in my child's energy levels or skin tone around the 3-to-6-month mark?
  • • What is my primary goal for my child's treatment (e.g., managing symptoms vs. pursuing a curative option like gene therapy)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Mutation Analysis of Exon 1 in the Hemoglobin Subunit Beta (HBB) Gene in Beta-Thalassemia.

    Kumar KS, Patil MM, Bulagouda R, Kadakol GS

    Cureus 2024; (16(7)):e65198 doi:10.7759/cureus.65198.

    PMID: 39176330
  2. 2

    Current status of beta-thalassemia and its treatment strategies.

    Ali S, Mumtaz S, Shakir HA, et al.

    Molecular genetics & genomic medicine 2021; (9(12)):e1788 doi:10.1002/mgg3.1788.

    PMID: 34738740
  3. 3

    Novel therapies in β-thalassaemia.

    Grech L, Borg K, Borg J

    British journal of clinical pharmacology 2022; (88(6)):2509-2524 doi:10.1111/bcp.14918.

    PMID: 34004015
  4. 4

    Clinical and hematological characteristics of beta-plus thalassemia and uncommon beta-chain hemoglobin variants in Northern Thailand.

    Rukwong P, Natesirinilkul R, Sathitsamitphong L, et al.

    Annals of medicine 2025; (57(1)):2551815 doi:10.1080/07853890.2025.2551815.

    PMID: 40888401
  5. 5

    Activin Receptor-Ligand Trap for the Treatment of β-thalassemia: A Serendipitous Discovery.

    Brancaleoni V, Nava I, Delbini P, et al.

    Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020075 doi:10.4084/MJHID.2020.075.

    PMID: 33194149
  6. 6

    Global analysis of erythroid cells redox status reveals the involvement of Prdx1 and Prdx2 in the severity of beta thalassemia.

    Romanello KS, Teixeira KKL, Silva JPMO, et al.

    PloS one 2018; (13(12)):e0208316 doi:10.1371/journal.pone.0208316.

    PMID: 30521599
  7. 7

    Molecular characteristics of thalassemia and hemoglobin variants in prenatal diagnosis program in northern Thailand.

    Mankhemthong K, Phusua A, Suanta S, et al.

    International journal of hematology 2019; (110(4)):474-481 doi:10.1007/s12185-019-02694-y.

    PMID: 31240559
  8. 8

    Compound Heterogeneous Sickle Cell-B+ Thalassemia Incidentally Discovered Through Cytological Examination of a Fine-Needle Aspiration Specimen from an Aneurysmal Bone Cyst in a Young Child: A Case Report.

    Meliti A, Muftah S, Saleh D, Habibullah N

    Cureus 2023; (15(1)):e33594 doi:10.7759/cureus.33594.

    PMID: 36779144
  9. 9

    Rare double heterozygosity for poly A(A〉 G) and CD17(A〉 T) of beta thalassemia intermedia in a Chinese family.

    Xie J, Zhou Y, Xiao Q, et al.

    Hematology reports 2019; (11(3)):7911 doi:10.4081/hr.2019.7911.

    PMID: 31579136
  10. 10

    Beta thalassemia syndromes: New insights.

    Dordevic A, Mrakovcic-Sutic I, Pavlovic S, et al.

    World journal of clinical cases 2025; (13(10)):100223 doi:10.12998/wjcc.v13.i10.100223.

    PMID: 40191679
  11. 11

    Alpha- and Beta-thalassemia: Rapid Evidence Review.

    Baird DC, Batten SH, Sparks SK

    American family physician 2022; (105(3)):272-280.

    PMID: 35289581
  12. 12

    The role of extracellular vesicles on the occurrence of clinical complications in β-thalassemia.

    Abdolalian M, Zarif MN, Javan M

    Experimental hematology 2023; (127()):28-39 doi:10.1016/j.exphem.2023.08.009.

    PMID: 37652128
  13. 13

    Hereditary disorders of ineffective erythropoiesis.

    King RA, Khoriaty R

    Blood cells, molecules & diseases 2025; (111()):102910 doi:10.1016/j.bcmd.2025.102910.

    PMID: 39938185
  14. 14

    XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia.

    Guillem F, Dussiot M, Colin E, et al.

    Haematologica 2020; (105(9)):2240-2249 doi:10.3324/haematol.2018.210054.

    PMID: 33054049
  15. 15

    Increasing prevalence of thalassemia in America: Implications for primary care.

    Sayani FA, Kwiatkowski JL

    Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.

    PMID: 26541064
  16. 16

    The mRNA-Binding Protein IGF2BP1 Restores Fetal Hemoglobin in Cultured Erythroid Cells from Patients with β-Hemoglobin Disorders.

    Chambers CB, Gross J, Pratt K, et al.

    Molecular therapy. Methods & clinical development 2020; (17()):429-440 doi:10.1016/j.omtm.2020.01.011.

    PMID: 32154328
  17. 17

    β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies.

    Barbarani G, Łabedz A, Ronchi AE

    Frontiers in genome editing 2020; (2()):571239 doi:10.3389/fgeed.2020.571239.

    PMID: 34713219
  18. 18

    Blessing in disguise; a case of Hereditary Persistence of Fetal Hemoglobin.

    Shaukat I, Pudal A, Yassin S, et al.

    Journal of community hospital internal medicine perspectives 2018; (8(6)):380-381 doi:10.1080/20009666.2018.1536241.

    PMID: 30559951
  19. 19

    Transient neonatal hemolytic anemia due to the novel gamma globin gene mutation HBG2:C.290T>C, p.Leu97Pro (hemoglobin Wareham).

    Gorfinkel L, Wachter F, Luo HY, et al.

    Pediatric blood & cancer 2023; (70(1)):e30067 doi:10.1002/pbc.30067.

    PMID: 36250986
  20. 20

    miRNA-Mediated Regulation of γ-Globin to β-Globin Switching: Therapeutic Potential in β-Hemoglobinopathies.

    Alotaibi D, Aldagdog F, Alramadhan S, et al.

    International journal of molecular sciences 2026; (27(3)) doi:10.3390/ijms27031203.

    PMID: 41683631
  21. 21

    Exploring the Clinical and Hematological Characteristics of Beta-Thalassemia Trait: A Comprehensive Analysis in a Tertiary Care Hospital Setting.

    E Y, Vasudevan S, Sonti S, et al.

    Cureus 2024; (16(5)):e61093 doi:10.7759/cureus.61093.

    PMID: 38919232
  22. 22

    Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis.

    Traivaree C, Monsereenusorn C, Rujkijyanont P, et al.

    Journal of blood medicine 2018; (9()):35-41 doi:10.2147/JBM.S159295.

    PMID: 29695942
  23. 23

    The Evaluation of Results of Twenty Common Equations for Differentiation of Beta Thalassemia Trait from Iron Deficiency Anemia: A Cross-Sectional Study.

    Ebrahimpour Sadagheyani H, Sharafkhani R, Sakhaei S, et al.

    Iranian journal of public health 2022; (51(4)):929-938 doi:10.18502/ijph.v51i4.9255.

    PMID: 35936522

This page provides educational information about the genetics of Beta-thalassemia major. It is not intended to replace professional medical advice. Always consult a pediatric hematologist or genetic counselor regarding your child's specific diagnosis and care.

Stay up to date

Get notified when new research about Beta-thalassemia major is published.

No spam. Unsubscribe anytime.